Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Nanotechnology became the driving force behind various evolutionary changes in the scientific field.  Nanotechnology based drug delivery enhanced the efficacy of available medicaments and enabled to create entirely new medical products. Nanotechnology has opened the door to new innventions to stimulate the reconstruction of complex tissue structures. Nanoparticles are used to deliver the drug to the specific diseased cell where particles attract to the diseased cell and provide treatment. By this technique, we can minimize the damage of healthy cells in the body.

Nanotechnology-dependent detectors e.g. nanowires, nanotubes, nanoparticles, cantilevers, and nano arrays consume low sample and enhance fast detection of disease. Target based Nano probes (e.g. magnetic nanoparticles, quantum dots, and carbon nanotubes) provide a faster, less invasive and more accurate way for diagnose of diseases. Reporting in vivo efficacy of therapeutics and helping surgeons to locate tumors are other opportunities of nanotechnology.

Some nanotechnology-based drugs that are commercially available are- Abraxane, approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer. Doxil was approved by the FDA for the treatment of ovarian cancer.

The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.


  • Track 1-1Nano technology industrial safety
  • Track 1-2Nano technology for environment
  • Track 1-3Bio materials and nano biotechnology
  • Track 1-4Nano medicine and cancer therapy
  • Track 1-5Nano electronic devices
  • Track 1-6Applications of nanotechnology
  • Track 1-7Global investments in nanotechnology
  • Track 1-8Future prospects of nano technology
  • Track 1-9Nano chemistry
  • Track 1-10Nano Physics
  • Track 1-11Molecular Nanotechnology
  • Track 1-12Nano Biomechanics

Targeted drug delivery is a kind of drug delivery, a method of delivering medication to a patient in a manner that increases the concentration only in particular area of the body. The goal of a targeted drug delivery system is to prolong, localize and have a safe drug interaction with the diseased tissue. The advantages of the this drug delivery are 1. reduction in the frequency of the dosages taken by the patient 2. have an uniform effect of the drug, 3.reduction of drug side-effects 4. reduce fluctuation in circulating drug levels 5.maintain the optimum plasma and tissue drug levels in the body. A small portion of the medication reaches the affected organ in Chemotherapy  and roughly 99% of the administered drug does not reach the tumor site.

The following criteria must be taken into consideration while designing a targeted drug delivery: the drug property,the route of drug delivery, the targeted site, disease and the side effects of drug. There are two kinds- active targeted drug delivery such as antibody medications and passive targeted drug deliver such as the enhanced permeability and retention effect.


  • Track 2-1Strategies of drug targeting
  • Track 2-2Ideal characteristics
  • Track 2-3Pro drugs
  • Track 2-4Tumor targeted drug delivery
  • Track 2-5Targeted delivery applications

Drug delivery is the action of administering a medication into the body for a therapeutic effect through various routes. Drug delivery technology modifies drug release profiles, pharmacokinetic parameters to improve product efficacy as well as patient convenience. Conventional routes cannot deliver compounds such as proteins, antibodies, vaccine and gene based drugs because these routes are susceptible to enzymatic degradation or cannot be absorbed into the systemic circulation efficiently due to large molecular size and charge issues.

Technologies include controlled needle-free devices, sustained, controlled transdermal delivery technology and penetration matrix technology for non-invasive delivery. Many innovative technologies for effective drug delivery have been developed that includes implants, nanotechnology, cell and peptide encapsulation, micro fabrication, chemical modification.

Biotechnology advances are leading to develop medications to target diseases more effectively and precisely.

Nanotechnology delivers drugs to targeted cells by nanoparticles. The overall drug consumption and side-effects are lowered significantly by depositing the active drug in the particular site and preventing administration of booster doses. Nanotechnology based devices are less invasive. They can be safely implanted inside the body as biochemical reaction times are much shorter.


  • Track 3-1Needle free technology
  • Track 3-2Jet injectors for vaccine delivery
  • Track 3-3Nano technology applications
  • Track 3-4Formulation of poorly soluble compounds
  • Track 3-5Latest controlled release technologies
  • Track 3-6Self emulsifying drug delivery system
  • Track 3-7Advances in GRDDS
  • Track 3-8Particle size reduction techniques
  • Track 3-9Site specific delivery
  • Track 3-10In vitro and invivo studies

The goal of drug delivery systems is to deliver medications to specific target parts of the body through a medium that can control the therapy’s administration. To achieve this goal, researchers are switching to advances in the worlds of micro- and nanotechnology.

The recent advances in the peptide,protein drug delivery systems are PEGylation and Depo-foam technology. Cell-penetrating peptides (CPPs) act as cargo carriers and constitute current medical research. CPPs to transport hydrophilic macromolecules into cells, thus, assist to execute biological functions. CPPs do not destroy the integrity of the cell membranes so they are considered more efficient and provide new avenues for research and applications in life sciences.

Needle-free drug delivery systems are novel ways to introduce various medicines to patients. PowderJect Pharmaceuticals one of the first companies to develop a needle-free technology for injecting powdered drugs into the skin. Needle free devices can take the form of power sprays, edible products, inhalers, and skin patches

Transdermal patches are user-friendly, convenient, painless and offer improved patient compliance.

Nano drug delivery systems such dendrimers, fullerence, nano pores, nanotubes, nano shells, quantum dots, , nanovaccines, revolutionized drug delivery systems. Thus nanomaterial can be used for strategic development of new drug delivery systems and reformulate existing.

Anti-cancer drugs such as loperamide and doxorubicin bound to nanomaterial have been shown to cross the blood-brain barrier.


  • Track 4-1Biomarkers in targeted drug delivery
  • Track 4-2CNS targeted drug delivery system
  • Track 4-3New drug carriers
  • Track 4-4Micro chip technology
  • Track 4-5Implant devices
  • Track 4-6Remote controlled delivery
  • Track 4-7Novel degradable polymers
  • Track 4-8Transdermal controlled release system
  • Track 4-9Latest advances in cancer therapy
  • Track 4-10Invitro drug release characterization models

Nanoparticles are generally less than 100 nm in dimension and consist of different biodegradable materials such as natural or synthetic polymers, lipids, or metals. Nanoparticles are taken up by cells more efficiently than larger micromolecules. Nanoparticles have high surface area to volume ratio thus allowing many functional groups for attachement. The small size of nanoparticles allows them to accumulate at sites.    

Nano particles can (1) enhance the efficacy and minimize adverse reactions associated with drugs; (2) enable new classes innovations; and (3) encourage the re-investigation of pharmaceutically suboptimal but biologically active new molecules that were previously considered undevelopable.

Nanoparticles are used in drug delivery to improve the uptake of poorly soluble drugs.

As per BCC Research the global market for nanoparticles in the life science forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%.


  • Track 5-1Nanoparticles Fabrication and Characterization
  • Track 5-2Carbon nano tubes

Innovative, non-invasive delivery includes improvement of patient acceptability and compliance, improvement in public safety, decrease of administration costs and a reduction of adverse effects. Enzyme degradation, acid degradation, hydrolysis and low permeability of intestinal epithelium in the GI tract surfaces make oral administration a non-viable delivery method. Proteins are administered parenterally as oral administration cause low bioavailability in the GI tract. It has become a challenge to achieve consistent and adequate bioavailability levels for oral administration.

Economic and financial barriers also stand in the way of implementing nano medicine. The limited availability of reimbursement by public and private health insurers for expensive new diagnostic tests has emerged as a major impediment to the deployment of personalized medicine. Nanoproducts encounter even greater hurdles because of their costs and complexity,  cytotoxicity of nanoparticles are  main concern of future research.

Advances in medical science, research and development (R&D) are changing the dynamics of the life science industry which includes pharmaceuticals and healthcare. The development of new drugs enhances the development of different drug delivery systems, which is further driven by innovation in technology, R&D and scientific advancements. Advances in understanding human diseases and medical treatments are opening new opportunities in the pharma industry. A better technology for drug administration or delivery is in demand now.


  • Track 6-1Paediatric and geriatric drug delivery
  • Track 6-2Nanotechnology drug delivery
  • Track 6-3Transport to CNS
  • Track 6-4Barriers to drug delivery in tumors
  • Track 6-5Challenges and barriers of occular drug delivery
  • Track 6-6Formulation design of poorly soluble drugs
  • Track 6-7Drug absorption barriers in intestine
  • Track 6-8Transport of biopharmaceuticals

One of the biggest challenges in the drug discovery and development for CNS disorders is to achieve significant blood–brain barrier (BBB) penetration.

Many drugs do not have high lipid solubility, low molecular size and positive charge to traverse BBB. The issues associated with the blood–brain barrier are 1. The drug produced allows only a small portion to pass through the barrier 2. Binding to other proteins in the body makes the drug ineffective or pass through the barrier with that adhered protein. 3. The presence of enzymes in the brain that could render the drug inactive. All of these problems must be addressed to deliver effective drugs to the brain.

Developed strategies enhance the capacity of drug to cross the BBB by modifying the drug or by coupling it to a vector for receptor-mediated or adsorption-mediated transcytosis.

Compounds using BBB technology in the clinical development would reach approximately eight by 2019. The global market for BBB technologies was valued at $38.7 million in 2014. The market is expected to grow to $471.5 million by 2019, and register a tremendous 64.9% CAGR from 2014 through 2019.


  • Track 7-1Anatomy and physiology of brain
  • Track 7-2New techniques of drug transport
  • Track 7-3Nano robotic carriers for drug delivery to brain
  • Track 7-4Receptor mediated permabilitizers
  • Track 7-5Microbubbles enhanced focused ultra sound
  • Track 7-6Peptide radio pharmaceuticals
  • Track 7-7Problems faced during drug delivery to brain
  • Track 7-8Chimeric peptides

It is defined as the method by which a drug is delivered can have a significant effect on its efficacy i.e. the drug become more efficacient in order to minimize drug degradation, adverse effects and to increase the bioavailability to produce betterresult. NDDS covers various aspects like pharmacokinetics & pharmacodynamics, non-specific toxicity, immunogenicity, bio recognition, and drug’s efficacy based on preferable approaches that include polymer science, pharmaceutical technology, dispensing pharmacy, packaging technology, bio conjugate chemistry, and molecular biology.


  • Track 8-1Transmucosal Drug Delivery Systems
  • Track 8-2Modified Drug Delivery Systems
  • Track 8-3Magnetically Induced Drug Delivery System
  • Track 8-4Sustained Drug Delivery Systems
  • Track 8-5Local Drug Delivery Systems
  • Track 8-6Ocular Drug Delivery Systems

A drug carrier enhances the selectivity, effectiveness and safety of drug administration. Drug carriers are mainly used to control the release of a drug into systemic circulation. This can be accomplished either by slow release of the drug over a long period of time (typically diffusion) or by triggering the release at the  target by stimulus, which include pH changes, application of heat and activation by light. Drug carriers improve the bioavailability of poorly water soluble drugs or membrane permeable drugs.

An ideal drug delivery vehicle must be non-toxic, non-immunogenic, biocompatible and  biodegradable Different methods of drug attachment to the carriers include adsorption, integration, encapsulation, and covalent bonding.


  • Track 9-1Formulation of Drug Delivery Vehicles
  • Track 9-2Physio-chemical properties

Peptides and proteins have more potential as drug delivery systems. Compared with the small size drugs, peptides and proteins can be highly selective as they have multiple contact points with their target. Increased selectivity results in decreased side effects and toxicity. Peptides can be designed to target a broad range of molecules and provide opportunities in oncology, infectious disease and endocrinology fields. The market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market .At present there are over 100 approved peptide-based drugs in the market. The pharmaceutical scientists have approaches to develop the protein and peptide delivery formulations by noninvasive routes.

Gene therapy is defined as incorporation of genetic material i.e, DNA or RNA, in the cellular gene regulation system, either to correct the expression of a malfunctioning gene or to modulate the cellular functions. Nanotechnology advances gave rise to the development of nanoparticle-DNA delivery systems. Gene delivery is an important part of genome evolution. Gene delivery utilizes non-immunogenic vectors capable of cell specificity that can deliver an adequate amount of transgene expression to cause the desired effect. Gene therapy advanceshave enabled a variety of new methods and gene targets to be identified for possible applications. Gene delivery has been utilized to generate a hybrid biosynthetic vector to deliver a possible vaccine.


  • Track 10-1Protein therapeutics
  • Track 10-2Polymers for delivery of proteins
  • Track 10-3Nano technology for protein delivery
  • Track 10-4Cancer targeting peptides
  • Track 10-5Cell penetration peptides and cell targeting
  • Track 10-6Challenges in protein drug delivery
  • Track 10-7Recent trends in peptide drug delivery
  • Track 10-8Genetics and genomic medicine
  • Track 10-9Gene mapping
  • Track 10-10Regulatory and safety aspects of gene therapy
  • Track 10-11Ethical issues in gene therapy
  • Track 10-12Advanced gene therapeutics
  • Track 10-13Markets and future prospects of gene therapy
  • Track 10-14Peptide Vector for Biologics Brain Delivery
  • Track 10-15Protein Formulation & Aggregation

Pharmacokinetics describes how the medicament gets influenced after administration, followed by absorption, distribution, metabolism mechanisms and excretion of the drug substance. Pharmacokinetic knowledge assists prescribers to adjust dosage accurately and precisely. Clinical kinetics is defined as the applications of pharmacokinetic principles in the safe and adequate management of individual patient. Toxic pharmacokinetics is defined as the applications of pharmacokinetic principles to the designation, behaviour and interpretation of drug safety evaluation studies.

Pharmacodynamics describes biochemical, physiological, and molecular effects of drugs on the body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical reactions. The pharmacological response depends on the drug binding to its target. The effect of drug presence at the site of action is measured by drug-receptor binding.


  • Track 11-1Dose- response relationship
  • Track 11-2Receptor binding and effects
  • Track 11-3Dose calculation
  • Track 11-4Therapeutic window
  • Track 11-5Toxicodynamics
  • Track 11-6pharmacokinetics Models
  • Track 11-7Clinical pharmacokinetics
  • Track 11-8Multicellular pharmacodynamics
  • Track 11-9Factors influencing bioavailability
  • Track 11-10Hepatic first-pass effect
  • Track 11-11In vitro Bioequivalence

Drug discovery is the process in which potential new medicines are recognized and comprises an effective range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies plays a key role in drug discovery for efficacy and safety assessment, in particular for translation from the non-clinical to clinical field and process of drug discovery include  the identification , synthesis, characterization, screening, and assays for therapeutic efficiency and modern drug discovery involves the identification of screening areas, medicinal chemistry and optimization of those areas to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability.

FDA provides scientific and regulatory advice to bring new therapies to market. In 2018, FDA has approved 43 new drugs which are currently in the market. Every year, CDER approves series of new drugs and biological products. The availability of new drugs represents new treatment options for patients and advances in health care. Some of these are often innovative new products that never before have been used in clinical practice. A new chemical entity (NCE) is a drug that contains no active molecule that has been approved by the FDA in any other application submitted under the Federal Food, Drug, and Cosmetic Act.


  • Track 12-1Computer Aided Drug Design (CADD)
  • Track 12-2Insilco Drug Discovery
  • Track 12-3Novel Detection Technologies and Drug Discovery
  • Track 12-4New Chemical Entity Exclusivity Determinations
  • Track 12-5Statutory and regulatory framework
  • Track 12-6NME versus NCE

Pharmacovigilance and Risk Management comprises set of pharmacovigilance activities designed to identify, characterise, prevent or minimize risks related to medicinal products which  includes the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO’s, pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates. Pharmacovigilance legislation focus on the rules and laws to follow in Pharmacovigilance practice. The Role of Pharma industries in the improvement of pharmacovigilance systems plays a crucial role to maintain the safety data, Detection and Evaluation of drug safety signals through medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines

Prescription Safety is the pharmacological science ensuring security and related to the aggregation, area, assessment, watching, and repugnance of hostile side effects with pharmacological movement of pharmaceutical things. As per  US FDA a drug is seen as protected by  its look, collecting technique and delayed consequences of animal testing and clinical tests. In this conference, we look at Drug security and its applications in various fields, for instance, Software, Training.


  • Track 13-1Information technology in pharmacovigilance and promoting companies
  • Track 13-2Review of softwares used in pharmacovigilance and clinical trials
  • Track 13-3Implementation of Risk Minimization Plans
  • Track 13-4Good reporting practices
  • Track 13-5Interpreting safety signals
  • Track 13-6Randomized clinical trials
  • Track 13-7Ethical and social aspects of drug use
  • Track 13-8Significance of pharmacovigilance
  • Track 13-9Pharmacovigilance and healthcare system
  • Track 13-10Pharmacovigilance legislation
  • Track 13-11Role of pharma industries in the improvement of pharmacovigilance system
  • Track 13-12Detection and evaluation of drug safety signals through manual and medical devices reporting

Materials are called “smart” when these materials have the ability to respond to stimuli and have high potential in delivery systems. The drug delivery to specific parts in the human body using smart materials has been approaching the forefront place in research for the past few decades. Materials for delivering drugs that do not interact non-specifically within the body must design drug carriers

Polymers have played an important role in the advancement of drug delivery technology by providing controlled release of agents in constant doses over longer duration and release of both hydrophobic and hydrophilic drugs. The greatest advantage of polymers is their ability to chemical modification, resulting in defined chemical composition, surface functionality and the potential for three-dimensional structures. Several polymers widely used are synthetic polymers and natural polymers.

Nano materials are used in controlled drug delivery. Drug-delivery systems can be designed with controlled composition, shape, size and morphology. Nanoparticles surface properties can be manipulated to increase solubility, immunocompatibility and cellular uptake.

Natural gums are widely used in the drug delivery system because of their wide availability, inexpensiveness.


  • Track 14-1Delivery materials for siRNA therapeutics
  • Track 14-2Proteins and gene delivery
  • Track 14-3Hydrogels for drug delivery
  • Track 14-4Tissue targeting nano particles
  • Track 14-5Regulatory aspects
  • Track 14-6Natural gums

Novel drug delivery systems address the drawbacks of the traditional drug delivery systems. We have a knowledge of Ayurveda. So it is important to integrate novel drug delivery system and Indian Ayurvedic medicines to combat serious diseases.

Reasons for using herbal medicines are 1.  Growing concern over the reliance and safety of drugs 2.Failure of modern medicine to treat most common health conditions   3. Natural medicines are producing better results without adverse effects.

Novel herbal formulations like polymeric herbal Nano-carriers, phytosomes, herbosomes, pro-niosomes, Nano emulsions, microsphere, transferosomes, implants and ethosomes has been reported using bioactive plant extracts. Advantages include Solubility, bioavailability enhancements, reduced toxicity, improved pharmacological activity, sustained delivery, and protection from physical and chemical degradation. Many formulations are produced from herbal drugs such as curcumin, quercetin, silybin, bilobalide, marsupsin, andrographolide.

According to WHO due to poverty and lack of access to modern medicine as well as self-belief, about 65-80% of the world's population living in developing and developed countries depends on plants for primary health care facilities.


  • Track 15-1Herbal remedies
  • Track 15-2Pharmaceutical aspects of herbal formulations
  • Track 15-3Clinical research of herbal drugs
  • Track 15-4Bio pharmaceutics of herbal drugs
  • Track 15-5Materials and methods of herbal drug delivery
  • Track 15-6Nano particles in herbal drug delivery
  • Track 15-7Recent developments in herbal formulation
  • Track 15-8Marketed herbal drug formulations
  • Track 15-9Future prospects

Pre-formulation studies are important for various phases of clinical trials. Pre- formulation studies act as the first step as well as the scientific foundation for formulation design and development. These studies provide guidance in selection of drug, excipients, to determine chemical composition, physical pattern and assist in adjustment of pharmacokinetic profiles. Improving public safety measures and intensifying product quality, safety, accuracy are the other characteristics.

The main purpose of pre-formulation studies is to improve compatibility with the other ingredients and develop stable, potent and safe dosage form. Physico-chemical parameters, drug solubility studies, partition coefficient, dissolution kinetics, polymorphism and stability profiles play a significant role in pre-formulation studies. These studies furnish the information regarding the degradation process, toxic effects and adverse conditions. So Pre-formulation is an interdisciplinary basis in drug development.

Formulation is defined as the process in which different chemical substances including the active ingredient are compounded to produce a final dosage form. Developed formulations should be stable, safe and acceptable to the patient.


  • Track 16-1Product Design to commercial dosage form
  • Track 16-2Preclinical formulations
  • Track 16-3Biopharmaceutical support in formulation
  • Track 16-4Types of Formulation: Enteral, Parenteral and Topical
  • Track 16-5Evaluation parameters in preformulation studies
  • Track 16-6Environment, health and safety considerations
  • Track 16-7Preformulation studies for generic products
  • Track 16-8Drug- excipient compatability studies
  • Track 16-9Application of Analytical techniques in pre- formulation studies
  • Track 16-10Drug formulation procedures
  • Track 16-11Formulation from plant extracts
  • Track 16-12Academy and industry perspectives

Vaccine is a material that induces an immunologically mediated resistance to a disease. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Vaccines though exceptionally selective and specific in reacting with antibodies often fail to show reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. These vaccines require boosting with agents called adjuvants in order to induce an effective immunity. Adjuvants potentiate the immunostimulatory property of the antigen and are non-immunogenic, nontoxic, and biodegradable in nature.

Conventional immunization regimen involves prime doses and booster doses. Immunization failed as patients neglect the booster doses. These reasons led the development of new generation of prophylactic and therapeutic vaccines to promote effective immunization. Vaccines allow for the incorporation of doses of antigens so that booster doses are no longer needed as antigens are released slowly in a controlled manner. Attempts are being made to deliver vaccines through carriers as they control the spatial and temporal movement of antigens to immune system thus leading to their sustained release and site targeting. Carrier systems such as liposomes, microspheres, nanoparticles, dendrimers, micelles and ISCOMs are being investigated and developed as vaccine delivery systems


  • Track 17-1Vaccine design and development
  • Track 17-2Vaccine adjuvents and delivery technologies
  • Track 17-3Cancer vaccines and immuno therapy
  • Track 17-4Dendritic cell based vaccines and development
  • Track 17-5Pain free vaccine delivery system
  • Track 17-6DNA delivery technologies
  • Track 17-7Vaccines for infants, children and adults
  • Track 17-8Clinical evaluation of vaccines
  • Track 17-9Current challenges of vaccine delivery
  • Track 17-10Market analysis of vaccines

Activities have been increased regarding the development and research on various printing techniques in formulation of dosage forms. These technologies offer flexibility in manufacturing, pave the way for personalized dosing and dosage forms.

Drug delivery from 3-dimensional (3D) structures is quick growing area of research. 3DP can design solid dosage forms with variable densities and diffusivities, complex internal geometries, multiple drugs and excipients.

3DP uses computer aided technology and programme to transform 3D computer aided designs (CAD) into life-changing products. These develop more effective and patient-friendly pharmaceutical products as well as bio-inspired medical devices. Levetiracetam (SPRITAM®) tablet a pharmaceutical product is developed by using 3DP technology.

3DP offers advantages like (a) high production rates due to its fast operating systems, (b) ability to achieve high drug-loading with desired accuracy mainly for potent drugs that are applied in small amount , (c) reduction of material wastage that can save in production cost and (d) amenability to pharmaceutical active ingredients including poorly water-soluble drugs, proteins as well as drug with narrow therapeutic windows.

3D structures can be printed on a variety of surfaces with characteristic permeability, porosity, hydrophobicity/hydrophilicity and surface energy. Scientists in collaboration with CAD designers have produced new medical devices ranging from pharmaceutical tablets to surgical transplants of the human face and skull, spinal implants, prosthetics, human organs and other biomaterials.


  • Track 18-1Printing technologies in fabrication of drug delivery
  • Track 18-2Computer aided tissue engineering
  • Track 18-3Inkjet powder bed printing
  • Track 18-4Electro spinning and allied technologies
  • Track 18-5Quality control of printed systems
  • Track 18-6Personalized products and individual dosing
  • Track 18-7Future challenges

Clinical trial is a part of clinical research that follows particular protocol, or plan of action. Clinical trials are mainly performed to obtain data on safety and efficacy of the new developed drug, this data is mandatory for further approval of the drug and to bring it into the market. Clinical trials, especially those taking new medications, regularly begin after effective examines.

Clinical trials are classified into 4 types. The fourth trial occurs after the FDA has cleared a specific medication or treatment and keeps on following the security of the treatment.  A clinical review includes inquire of utilizing human volunteers (called members) that add to therapeutic learning. Test potential medicines in human volunteers to see whether they ought to be endorsed for more extensive use in the all-inclusive community

The clinical trials market size was valued at USD 40.0 billion in 2016 and is expected to grow at a CAGR of 5.7% until 2025.

The interventional study design is the most essential method of conducting clinical trials across the globe. As per the statistics provided by the U.S. FDA, over 126,000 trials are currently being conducted by means of this method. Based on this indication, oncology is anticipated to witness the fastest growth.


  • Track 19-1Pre-Clinical Testing
  • Track 19-2Classification of various adverse drug reactions
  • Track 19-3Clinical trials on drugs used in respiratory disorders
  • Track 19-4Advanced Information technology in clinical trials
  • Track 19-5Regulatory authorities and ethics committee
  • Track 19-6Multi center trials and monitoring
  • Track 19-7Alternative trials design and models
  • Track 19-8Data collection and quality control
  • Track 19-9Bioassay and its types
  • Track 19-10Scientific Models for Pre-Clinical and Clinical Trials
  • Track 19-11pplications of biomarkers in clinical trials

Regulatory affairs is a new profession which developed from the governments desire to protect public by controlling the safety and efficacy of products in areas including pharmaceuticals , industrial pharmacy, veterinary medicines, medical devices. Regulatory Affairs is involved in the development of new medicines from early stage, by incorporating regulatory principles, by preparing and submitting the relevant regulatory documents to health authorities. Regulatory Affairs is actively involved in every step of development of a new medicine and in the post-marketing activities with authorized medicines. The Regulatory Affairs department is an essential part of the organizational structure of pharmaceutical industry. Internally it assist at the interphase of drug development, manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities.


  • Track 20-1Regulatory Affairs Filing and Documentation
  • Track 20-2Enhancing Regulatory Science for Public Health
  • Track 20-3Meeting the Challenges for Regulating
  • Track 20-4Patent and types of Patent Application
  • Track 20-5Copyrights
  • Track 20-6Trademark
  • Track 20-7Infringement
  • Track 20-8Role of Patent Co-operation Therapy
  • Track 20-9Drug Regulations and Organizations
  • Track 20-10Global Pharma Products Registration
  • Track 20-11Intellectual Property Law for Generics and Innovator Rights
  • Track 20-12Safety and Quality Regulation in Labelling

The biopharmaceutical sector in US enjoys 17% of all domestic R&D funded by the country and in return gave $2.5 trillion cumulative addition in economic output in 2016. Companies involved in the pharmaceutical manufacturing have grappled in recent years owing to the largest waves of drug patent expirations in history. As a consequence enabling low-price generic drugs to inundate the market.  Many pharmaceutical manufacturers have contended with intensifying competition from generic manufacturers and cutting into revenue growth. Until the next five years till 2022, investments in research and development that generate a high return will occur as many pharmaceutical manufacturers strengthen their drug pipeline with orphan drugs.

Recently, engineers have shown inclination to single-use, modern and continuous manufacturing technologies to improve efficiency, safety and minimize scale-up steps and technology transfer problems in the pharmaceutical industry. Lot of these innovations are driven by updates instigated by the FDA. The changes are inevitable; especially in the already aging biopharmaceutical sector of the industry, where original processes are overly complex and are characterized by inefficiency, and occasionally, inherent unpredictability.


Pharmaceutical chemistry is a branch that includes synthetic organic chemistry, pharmacology and biological specialties, where they involve in the design of drugs, synthesis and development. Pharmaceutical chemistry focuses on small molecules / organic entities encompassing synthetic organic chemistry, aspects of natural product chemistry and computational chemistry in close relation with chemical biology, enzymology and structural biology, together with the goal of discovery and drug development of new different agents. Speaking in practical terms, it involves chemical aspects of identification and, subsequently, a systematic and exhaustive synthetic alteration of new chemical entities to make them appropriate for use. It includes synthetic and computational aspects of the study of drugs and agents existing in the development in relation to their biological activities to understand their structure-activity relationship (SAR). Pharmaceutical chemistry focuses on the aspects of medicines and aims to ensure the adequacy, efficiency of the purposes of the medicines.


  • Track 22-1Physicochemical and biological factors that contribute to drug action
  • Track 22-2Medicinal Radio compounds or Radiopharmaceuticals
  • Track 22-3Global Pharmaceutical Policy
  • Track 22-4Impurities and Impurity Profile Significance in API
  • Track 22-5Design of Safer Chemicals and Products
  • Track 22-6Process Chemistry Considerations
  • Track 22-7 Structure-activity relationships of drug Moiety
  • Track 22-8Synthetic chemistry including combinatorial methods
  • Track 22-9In vivo and in vitro biotransformations of drugs
  • Track 22-10Modeling and designing of small compounds

Chromatography and Mass Spectrometry are extensively used in the drug development stage of generic products. The ICH Q3B guidelines address the reporting threshold, identification threshold, and threshold for impurities in the product.  Chromatography (LC) and Gas Chromatography (GC) are extensively used to analyze stable compounds. Labile compounds require derivatization prior to Liquid Chromatography or Gas Chromatography analysis. For certain analyses, Liquid Chromatography- Ultraviolet Detection (LC-UVD) and Gas Chromatography-Flame Ionization Detection (GC-FID) techniques may be deemed suitable. However, Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) are techniques of choice when higher specificity and sensitivity are required. Gas Chromatography-Electron Capture Detection (GC-ECD) techniques are commonly used for halogenated PGIs/GIs to enhance sensitivity and selectivity. Some spectroscopic techniques like Nuclear Magnetic Resonance (NMR), light scattering, and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) are used in analyzing PGIs/GIs.


  • Track 23-1Novel Approaches to Analytical and Bioanalytical Methods
  • Track 23-2Regulatory issues and biosafety challenges in bioanalysis
  • Track 23-3Physical Analytical Methods
  • Track 23-4Titrimetric Methods
  • Track 23-5Solid-State Analysis
  • Track 23-6Degradation and Impurity Analysis For Pharmaceutical Drug Candidates
  • Track 23-7Clinical Pharmacy and Therapeutics

A biopharmaceutical, otherwise called a biologic therapeutic item or biologic, is any restorative item made in, extricated from, or semi orchestrated from organic sources. Not quite the same as synthetically incorporated pharmaceuticals, they incorporate immunizations, blood segments, allergenic, substantial cells, quality treatments, tissues, recombinant protein and living cells used as a part of cell treatment. Biologics can be made of sugars, proteins, nucleic acids, complex mixtures of these substances, from live cells or tissues. They are confined from normal sources—human, creature, or microorganism. Phrasing encompassing biopharmaceuticals fluctuates amongst gatherings and elements, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class. Some offices utilize the terms natural  items or remedial organic item to allude particularly to macromolecular items like protein-and nucleic acid–based drugs, recognizing them from items like blood segments or antibodies which are extricated specifically from a natural source Gene-based and cell biologics are at the front line of biomedical research, and might be utilized to treat therapeutic conditions for which no different medications are accessible.


  • Track 24-1Bio-analytics for biosimilars
  • Track 24-2Extrapolation and interchangeability
  • Track 24-3Legal considerations for biosimilars
  • Track 24-4Biosimilar uptake and market considerations
  • Track 24-5challenges and regulatory approach for biosimilars
  • Track 24-6Future of next generation biosimilars

Packaging is one of the largest industrial sector in the world that worth several billions. Pharmaceutical packaging are of 3 types, which are: solid packaging, semi-solids packaging and liquid packaging. The pharmaceutical packaging is a very profitable industry and it is estimated that for 2022 it will reach USD. 8.24 billion. Pharmaceutical packaging represents a meagre percentage of this colossal market. The Global Logistics Market is expected to grow at a CAGR of 7.0% from 2016-2021 and CAGR of 5.6% from 2021-2027. By 2020, pharma cold-chain logistics will be worth $16.7 billion, and non-cold chain at $77.1 billion. The market was estimated at $14.84bn in 2016 and is expected to grow to $28.75bn in 2027.


  • Track 25-1Future of packaging materials
  • Track 25-2Regulatory considerations-China, US, EU, Pharmacopoeia
  • Track 25-3Packaging for patient compliance
  • Track 25-4Packing technology for drug delivery systems
  • Track 25-5Serialization implementation challenges for pharma companies

A nonspecific medication is characterized as "a medication item that is referred to a brand/reference medication item in measurements of quality, quality, execution attributes, and planned utilization." It is characterized as a term alluding to any medications showcased under its concoction name without any publicity as opposed to the promoted mark name under which the medication is sold out. They are not connected with a specific organization but nonspecific medications are liable to the directions of the nation’s admirations where they are apportioned. Worldwide nonspecific is marked with the name of the maker and the received name of the medication. A nonspecific medication and OTC Drugs must have indistinguishable dynamic fixings.

Generic drugs allow access to health care for all Americans. They are brand-name drugs copies and are the same as those brand name drugs in dosage form, safety, efficacy, strength, administration routes, quality, performance and intended use. Health care professionals can be assured that FDA approved generic drugs have met the same standards as the innovator drug. All generic drugs approved by FDA should have the same high quality, strength, purity and stability as brand-name drugs. The generic manufacturing, packaging, and testing methods must pass the same quality standards as those of brand name drugs.


  • Track 26-1Generic drug manufacturing

Tissue Engineering is characterized as understanding the standards of tissues and its development by practical trade of deficient tissue for clinical utilization. Tissue building deals about the study of combination of cells, designing, materials strategies, physicochemical and biochemical components to replace or enhance natural tissues. Tissue Engineering utilize Scaffolds to form functional tissues and organs, which can be implanted back into the donor host with the use of engineering techniques and materials process along with some physicochemical factors. It is related to more than one branch which applies engineering knowledge as well as life science concepts towards the development of biological substitutes which can enhance or restore physiological characteristics of organ.

Regenerative Medicine is branch of translational research in tissue designing which manages the way towards supplanting, recovering human cells, tissues or organs to re-establish capacity. Instruments used to understand the results are tissue building, cell treatments, restorative gadgets and manufactured organs.


  • Track 27-1Tissue biomarkers
  • Track 27-2Tissue graft tolerance
  • Track 27-3Photodynamic therapy
  • Track 27-4Tissue mechanics & mechanobiology
  • Track 27-5Histopathology

Transdermal Drug Delivery system is a part of drug delivery system and involves more research. Drugs having long pharmacokinetic half-lives are considered to be unfit for transdermal application. By the increased number of marketing authorization applications along with recent scientific developments for transdermal patches, the need for clear guidance and reserach on specific requirements for this dosage form increased.

The emergence of technological innovations in transdermal patches is expected to provide the market with advances growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.


  • Track 28-1Advances in Intradermal Drug Delivery
  • Track 28-2Computational Modeling of Transdermal and Intradermal Delivery
  • Track 28-3Applications of Transdermal Delivery

Pharmaceutical technology is the scientific knowledge or technology utilized in pharmacy, pharma companies,pharmacology, toxicology and the pharmaceutical industry. It excludes design, techniques, devices and instrumentation in the manufacture, preparation, synthesis, compounding, dispensing, packaging, and accumulating of narcotic and other preparations used in diagnostic, to determine procedures and in the treatment of patients.


  • Track 29-1Pharmaceutical Research & Development
  • Track 29-2Pharmaceutical Technology Assessment
  • Track 29-3Quality assurance
  • Track 29-4Pharmaceutical industry
  • Track 29-5Pharmacological Technology advances
  • Track 29-6Bioinformatics and Computational Biology

Pharmacotherapy can be characterized as the treatment, counteractive action of disease by methods for medications of the synthetic or organic root. It positions among essential techniques for therapeutic treatment, together with surgery, physical therapy, radiations, and psychotherapy. Although it is practically difficult to appraise the correct degree of pharmacotherapy effect on human well-being, pharmacotherapy together with enhanced sanitation, eating regimen and better lodging has improved individuals. Phenomenal advancements in genomics and atomic science offer a plenty of new medication targets. The utilization of present-day manufactured strategies enhances the blend of medication in shorter circumstances than at any other time.


  • Track 30-1Application of NDDS in the pharmacotherapy of hyperlipidemia
  • Track 30-2Controlled drug delivery: therapeutic and pharmacological aspects
  • Track 30-3Impact of pharmacotherapy on DDS
  • Track 30-4Pharmacokinetics, pharmacodynamics of drugs and new DDS
  • Track 30-5Rational pharmacotherapy of the inner ear

The route of administration is the path through which the dosage form (active substance) is administered into the body for treatment of various diseases and disorders. Routes of administration are classified based on 1.the location at which the dosage form is applied 2. Target of action. These include oral, topical and enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).

Taking them correctly and understanding the right way to administer can reduce the risks. The route used to administer a drug depends on three main factors: 1. the part of the body being treated 2.the way the drug works within the body 3.the formula of the drug. These routes enhance the bio availability of drug molecule.

The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market analysis is based on route of administration, facility of use.


  • Track 31-1Factors governing choice of route
  • Track 31-2Channels of drug administration
  • Track 31-3Challenges in drug administration
  • Track 31-4Effects of routes of administration on drug discovery